CN103664905A - 盐酸坦度螺酮晶型ii及其制备方法 - Google Patents
盐酸坦度螺酮晶型ii及其制备方法 Download PDFInfo
- Publication number
- CN103664905A CN103664905A CN201310727772.0A CN201310727772A CN103664905A CN 103664905 A CN103664905 A CN 103664905A CN 201310727772 A CN201310727772 A CN 201310727772A CN 103664905 A CN103664905 A CN 103664905A
- Authority
- CN
- China
- Prior art keywords
- hydrochloric acid
- tandospirone
- crystal form
- preparation
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- ACVFJYKNBOHIMH-DPFKZJTMSA-N 99095-10-0 Chemical compound Cl.O=C([C@H]1[C@@H](C2=O)[C@]3([H])CC[C@]1(C3)[H])N2CCCCN(CC1)CCN1C1=NC=CC=N1 ACVFJYKNBOHIMH-DPFKZJTMSA-N 0.000 title abstract description 6
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 19
- 239000003814 drug Substances 0.000 claims abstract description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 119
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 claims description 72
- 229950000505 tandospirone Drugs 0.000 claims description 70
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 28
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- 230000015572 biosynthetic process Effects 0.000 claims description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 3
- 230000000966 norepinephrine reuptake Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 230000004044 response Effects 0.000 claims description 2
- 229940076279 serotonin Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 7
- 238000005516 engineering process Methods 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 238000010586 diagram Methods 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 238000005755 formation reaction Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 208000019901 Anxiety disease Diseases 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000012916 structural analysis Methods 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 235000019633 pungent taste Nutrition 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000000967 suction filtration Methods 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 201000010183 Papilledema Diseases 0.000 description 2
- 206010038886 Retinal oedema Diseases 0.000 description 2
- 206010064930 age-related macular degeneration Diseases 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 201000011195 retinal edema Diseases 0.000 description 2
- 239000000952 serotonin receptor agonist Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010034432 Performance fear Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000001353 anxiety effect Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000001782 photodegradation Methods 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310727772.0A CN103664905B (zh) | 2013-12-25 | 2013-12-25 | 盐酸坦度螺酮晶型ii及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310727772.0A CN103664905B (zh) | 2013-12-25 | 2013-12-25 | 盐酸坦度螺酮晶型ii及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103664905A true CN103664905A (zh) | 2014-03-26 |
CN103664905B CN103664905B (zh) | 2015-10-14 |
Family
ID=50303774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310727772.0A Active CN103664905B (zh) | 2013-12-25 | 2013-12-25 | 盐酸坦度螺酮晶型ii及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103664905B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106349227A (zh) * | 2014-06-06 | 2017-01-25 | 四川科瑞德制药股份有限公司 | 一种草酸坦度螺酮化合物 |
CN106749196A (zh) * | 2015-11-25 | 2017-05-31 | 四川科瑞德制药股份有限公司 | 一种5-羟色胺受体激动剂 |
CN106905301A (zh) * | 2015-12-22 | 2017-06-30 | 四川科瑞德制药股份有限公司 | 一种氮杂螺酮类化合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101880274A (zh) * | 2010-06-28 | 2010-11-10 | 北大国际医院集团西南合成制药股份有限公司 | 一种坦度螺酮及其类似物的制备方法 |
CN102264344A (zh) * | 2008-12-22 | 2011-11-30 | 爱尔康研究有限公司 | 递送有效浓度的活性剂至眼睛后段的局部眼用溶液组合物 |
-
2013
- 2013-12-25 CN CN201310727772.0A patent/CN103664905B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102264344A (zh) * | 2008-12-22 | 2011-11-30 | 爱尔康研究有限公司 | 递送有效浓度的活性剂至眼睛后段的局部眼用溶液组合物 |
CN101880274A (zh) * | 2010-06-28 | 2010-11-10 | 北大国际医院集团西南合成制药股份有限公司 | 一种坦度螺酮及其类似物的制备方法 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106349227A (zh) * | 2014-06-06 | 2017-01-25 | 四川科瑞德制药股份有限公司 | 一种草酸坦度螺酮化合物 |
CN106467520A (zh) * | 2014-06-06 | 2017-03-01 | 四川科瑞德制药股份有限公司 | 一种草酸坦度螺酮化合物 |
CN106749196A (zh) * | 2015-11-25 | 2017-05-31 | 四川科瑞德制药股份有限公司 | 一种5-羟色胺受体激动剂 |
CN106800550A (zh) * | 2015-11-25 | 2017-06-06 | 四川科瑞德制药股份有限公司 | 一种5‑羟色胺受体激动剂 |
CN106800550B (zh) * | 2015-11-25 | 2020-07-03 | 四川科瑞德制药股份有限公司 | 一种5-羟色胺受体激动剂 |
CN106749196B (zh) * | 2015-11-25 | 2020-07-03 | 四川科瑞德制药股份有限公司 | 一种5-羟色胺受体激动剂 |
CN106905301A (zh) * | 2015-12-22 | 2017-06-30 | 四川科瑞德制药股份有限公司 | 一种氮杂螺酮类化合物及其制备方法 |
CN106905302A (zh) * | 2015-12-22 | 2017-06-30 | 四川科瑞德制药股份有限公司 | 一种氮杂螺酮类化合物及其制备方法 |
CN106905302B (zh) * | 2015-12-22 | 2020-07-31 | 四川科瑞德制药股份有限公司 | 一种氮杂螺酮类化合物及其制备方法 |
CN106905301B (zh) * | 2015-12-22 | 2020-07-31 | 四川科瑞德制药股份有限公司 | 一种氮杂螺酮类化合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103664905B (zh) | 2015-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103755687B (zh) | 盐酸坦度螺酮晶型ⅰ及其制备方法 | |
CN103974949B (zh) | 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法 | |
CN105669564B (zh) | 脲类化合物、其制备方法、药物组合物、中间体及其应用 | |
CN105163727B (zh) | 刺激神经发生的异喹啉衍生物 | |
CN101910152A (zh) | 作为janus激酶抑制剂的4-吡唑基-n-芳基嘧啶-2-胺和4-吡唑基-n-杂芳基嘧啶-2-胺 | |
AU2014252584B2 (en) | Anti-angiogenesis compound, intermediate and use thereof | |
CN103664905B (zh) | 盐酸坦度螺酮晶型ii及其制备方法 | |
TW200526631A (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
CN105008333A (zh) | N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺的硫酸盐、其制备及其用途 | |
CA2962206A1 (en) | Crystalline forms of tyrosine kinase inhibitors and their salts | |
CN107337639A (zh) | 稳定的盐酸卡替洛尔及其制法和眼用药物组合物 | |
CN104496896B (zh) | 含磺酰脲结构的索拉非尼衍生物的制备及应用 | |
CN110272423A (zh) | 二氮杂四高立方烷类化合物、制备方法及其应用 | |
CN106905236B (zh) | 布南色林及其制备方法 | |
CN105566314A (zh) | 一种盐酸替扎尼定化合物 | |
CN115232090A (zh) | 6位取代二氢苯并[e][1,2,3]噁噻嗪2,2-二氧化类化合物及其制备与应用 | |
CN103910674A (zh) | 用于马来酸氟吡汀分析中的参比化合物 | |
AU2006237936A1 (en) | Method for producing alpha form crystals of sapropterin hydrochloride | |
CN109516991A (zh) | 一种枸橼酸托法替尼晶型化合物及其制备方法 | |
CN105175398A (zh) | 一种草酸坦度螺酮化合物 | |
CN106800550B (zh) | 一种5-羟色胺受体激动剂 | |
CN106397410B (zh) | 5-羟色胺受体激动剂及其制备方法和用途 | |
CN106397413B (zh) | 5-羟色胺受体激动剂及其制备方法和用途 | |
CN107311988B (zh) | 一种治疗阿尔茨海默病的药物 | |
CN105218528A (zh) | 一种l-酒石酸坦度螺酮化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: KERUIDE PHARMACEUTICAL CO., LTD., SICHUAN Free format text: FORMER OWNER: CHENGDU CREDIT PHARMACEUTICAL INVESTMENT CO., LTD. Effective date: 20150428 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610000 CHENGDU, SICHUAN PROVINCE TO: 646000 LUZHOU, SICHUAN PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150428 Address after: 646000 Luxian County City, Sichuan province Fu Town Industrial Park Applicant after: SICHUAN CREDIT PHARMA CO.,LTD. Address before: 610000 innovation service center of Chengdu hi tech Zone, Sichuan Applicant before: CHENGDU CREDIT PHARMACEUTICAL INVESTMENT Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP03 | Change of name, title or address |
Address after: 646000 national high tech Zone, Sichuan, Luzhou Province Pharmaceutical Industrial Park Patentee after: SICHUAN CREDIT PHARMACEUTICAL Co.,Ltd. Address before: 646000 Luxian County City, Sichuan province Fu Town Industrial Park Patentee before: SICHUAN CREDIT PHARMA CO.,LTD. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220328 Address after: 646100 Industrial Park, Fu Zhen Town, Luzhou, Sichuan, Luxian County Patentee after: Luzhou kered Pharmaceutical Co.,Ltd. Address before: 646000 Sichuan Luzhou national hi tech Industrial Park Patentee before: SICHUAN CREDIT PHARMACEUTICAL Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 646100 Industrial Park, Fu Zhen Town, Luzhou, Sichuan, Luxian County Patentee after: Sichuan Tiandao Pharmaceutical Co.,Ltd. Country or region after: China Address before: 646100 Industrial Park, Fu Zhen Town, Luzhou, Sichuan, Luxian County Patentee before: Luzhou kered Pharmaceutical Co.,Ltd. Country or region before: China |